CYP4Z1-IN-1_product_DataBase

Bioactivity	CYP4Z1-IN-1 (compound 7c) is a potent CYP4Z1 inhibitor, with an IC50 of 41.8 nM. CYP4Z1-IN-1 decreases the expression of breast CSCs stemness markers, spheroid formation, and metastatic ability as well as tumor-initiation capability in a concentration-dependent manner in vitro and in vivo[1].
Invitro	CYP4Z1-IN-1 (compound 7c) 显示出对乳腺 CSC (癌症干细胞)的抗增殖活性，IC50 为 483 ± 2.5 nM[1] 。CYP4Z1-IN-1 (0.8-51.2 μM, 24 h) 抑制乳腺癌细胞中干细胞标记物 (P-gp, Oct3/4, Nanog, ALDH1A1, 和 Sox2) 的表达[1]。CYP4Z1-IN-1 (0.8-51.2 μM, 24-48 h) 可减弱乳腺癌细胞的迁移和侵袭能力[1]。 Western Blot Analysis[1] Cell Line:
In Vivo	CYP4Z1-IN-1 (compound 7c) (2000 mg/kg，口服，连续 7 天)对小鼠没有明显的毒性和体重减轻[1]。CYP4Z1-IN-1 (12.8 μM, 72 h处理MCF-7 and MDA-MB-231 cells，然后细胞皮下植入小鼠腹股沟乳腺) 可阻断乳腺癌细胞的肿瘤启动能力[1]。 Animal Model:
Name	CYP4Z1-IN-1
CAS	2760611-38-7
Formula	C13H18N2O3
Molar Mass	250.29
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Yuan Y, et al. Identification of a Novel Potent CYP4Z1 Inhibitor Attenuating the Stemness of Breast Cancer Cells through Lead Optimization. J Med Chem. 2022 Dec 8;65(23):15749-15769.

PeptideDB